EP Patent

EP0208519A2 — Solubilized composition of hardly-soluble pharmaceutical product

Assigned to Takeda Pharmaceutical Co Ltd · Expires 1987-01-14 · 39y expired

What this patent protects

3-(n-Octedecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate solubilized with use of a salt of salicylic add or/and a salt of a bile acid can be administered as stable injenction without causing precipitation. A composition containing a reducing sulfur compound or a seq…

USPTO Abstract

3-(n-Octedecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate solubilized with use of a salt of salicylic add or/and a salt of a bile acid can be administered as stable injenction without causing precipitation. A composition containing a reducing sulfur compound or a sequestering agent besides the above mentioned ingredients can be stored for a long term even at room temperature as well as a cold place.

Drugs covered by this patent

Patent Metadata

Patent number
EP0208519A2
Jurisdiction
EP
Classification
—
Expires
1987-01-14
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.